These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1706 related items for PubMed ID: 29227344

  • 1. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX.
    Michelakos T, Pergolini I, Castillo CF, Honselmann KC, Cai L, Deshpande V, Wo JY, Ryan DP, Allen JN, Blaszkowsky LS, Clark JW, Murphy JE, Nipp RD, Parikh A, Qadan M, Warshaw AL, Hong TS, Lillemoe KD, Ferrone CR.
    Ann Surg; 2019 Apr; 269(4):733-740. PubMed ID: 29227344
    [Abstract] [Full Text] [Related]

  • 2. Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis.
    Choi JG, Nipp RD, Tramontano A, Ali A, Zhan T, Pandharipande P, Dowling EC, Ferrone CR, Hong TS, Schrag D, Fernandez-Del Castillo C, Ryan DP, Kong CY, Hur C.
    Oncologist; 2019 Jul; 24(7):945-954. PubMed ID: 30559125
    [Abstract] [Full Text] [Related]

  • 3. Surgery after FOLFIRINOX treatment for locally advanced and borderline resectable pancreatic cancer: increase in tumour attenuation on CT correlates with R0 resection.
    Marchegiani G, Todaro V, Boninsegna E, Negrelli R, Sureka B, Bonamini D, Salvia R, Manfredi R, Pozzi Mucelli R, Bassi C.
    Eur Radiol; 2018 Oct; 28(10):4265-4273. PubMed ID: 29679211
    [Abstract] [Full Text] [Related]

  • 4. CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma.
    Wagner M, Antunes C, Pietrasz D, Cassinotto C, Zappa M, Sa Cunha A, Lucidarme O, Bachet JB.
    Eur Radiol; 2017 Jul; 27(7):3104-3116. PubMed ID: 27896469
    [Abstract] [Full Text] [Related]

  • 5. Intraoperative Radiation Therapy (IORT) for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (BR/LA PDAC) in the Era of Modern Neoadjuvant Treatment: Short-Term and Long-Term Outcomes.
    Harrison JM, Wo JY, Ferrone CR, Horick NK, Keane FK, Qadan M, Lillemoe KD, Hong TS, Clark JW, Blaszkowsky LS, Allen JN, Castillo CF.
    Ann Surg Oncol; 2020 May; 27(5):1400-1406. PubMed ID: 31758284
    [Abstract] [Full Text] [Related]

  • 6. Borderline or locally advanced pancreatic adenocarcinoma: A single center experience on the FOLFIRINOX induction regimen.
    Garnier J, Ewald J, Marchese U, Gilabert M, Moureau-Zabotto L, Giovannini M, Poizat F, Delpero JR, Turrini O.
    Eur J Surg Oncol; 2020 Aug; 46(8):1510-1515. PubMed ID: 32146053
    [Abstract] [Full Text] [Related]

  • 7. FOLFIRINOX as Initial Treatment for Localized Pancreatic Adenocarcinoma: A Retrospective Analysis by the Trans-Atlantic Pancreatic Surgery Consortium.
    Janssen QP, van Dam JL, Doppenberg D, Prakash LR, van Eijck CHJ, Jarnagin WR, O' Reilly EM, Paniccia A, Besselink MG, Katz MHG, Tzeng CD, Wei AC, Zureikat AH, Groot Koerkamp B, Trans-Atlantic Pancreatic Surgery (TAPS) Consortium.
    J Natl Cancer Inst; 2022 May 09; 114(5):695-703. PubMed ID: 35157075
    [Abstract] [Full Text] [Related]

  • 8. Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial.
    Labori KJ, Bratlie SO, Andersson B, Angelsen JH, Biörserud C, Björnsson B, Bringeland EA, Elander N, Garresori H, Grønbech JE, Haux J, Hemmingsson O, Liljefors MG, Myklebust TÅ, Nymo LS, Peltola K, Pfeiffer P, Sallinen V, Sandström P, Sparrelid E, Stenvold H, Søreide K, Tingstedt B, Verbeke C, Öhlund D, Klint L, Dueland S, Lassen K, Nordic Pancreatic Cancer Trial-1 study group.
    Lancet Gastroenterol Hepatol; 2024 Mar 09; 9(3):205-217. PubMed ID: 38237621
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Neoadjuvant Radiotherapy After (m)FOLFIRINOX for Borderline Resectable Pancreatic Adenocarcinoma: A TAPS Consortium Study.
    Janssen QP, van Dam JL, Prakash LR, Doppenberg D, Crane CH, van Eijck CHJ, Ellsworth SG, Jarnagin WR, O'Reilly EM, Paniccia A, Reyngold M, Besselink MG, Katz MHG, Tzeng CD, Zureikat AH, Groot Koerkamp B, Wei AC, Trans-Atlantic Pancreatic Surgery (TAPS) Consortium.
    J Natl Compr Canc Netw; 2022 Jul 09; 20(7):783-791.e1. PubMed ID: 35830887
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Predictive factors for survival in borderline resectable and locally advanced pancreatic cancer: are these really two different entities?
    de Carvalho LFA, Gryspeerdt F, Rashidian N, Van Hove K, Maertens L, Ribeiro S, Hoorens A, Berrevoet F.
    BMC Surg; 2023 Sep 30; 23(1):296. PubMed ID: 37775737
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel for Neoadjuvant Treatment of Resectable and Borderline Resectable Pancreatic Head Adenocarcinoma.
    Dhir M, Zenati MS, Hamad A, Singhi AD, Bahary N, Hogg ME, Zeh HJ, Zureikat AH.
    Ann Surg Oncol; 2018 Jul 30; 25(7):1896-1903. PubMed ID: 29761331
    [Abstract] [Full Text] [Related]

  • 17. Patient outcome according to the 2017 international consensus on the definition of borderline resectable pancreatic ductal adenocarcinoma.
    Medrano J, Garnier J, Ewald J, Marchese U, Gilabert M, Launay S, Poizat F, Giovannini M, Delpero JR, Turrini O.
    Pancreatology; 2020 Mar 30; 20(2):223-228. PubMed ID: 31839458
    [Abstract] [Full Text] [Related]

  • 18. Impact of Margin Status on Survival in Patients with Pancreatic Ductal Adenocarcinoma Receiving Neoadjuvant Chemotherapy.
    Schmocker RK, Delitto D, Wright MJ, Ding D, Cameron JL, Lafaro KJ, Burns WR, Wolfgang CL, Burkhart RA, He J.
    J Am Coll Surg; 2021 Apr 30; 232(4):405-413. PubMed ID: 33338577
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 86.